Modulation of Fatty Acid Metabolism by Glucagon in Man. II. Effects in Insulin-deficient Diabetics
Overview
Authors
Affiliations
The potential role of glucagon in the pathogenesis of diabetic ketogenesis was examined by intravenous glucagon administration (1.0 mug/kg. body weight) in five insulin-dificient diabetic subjects. The metabolic response was defined by examining the changes in the plasma concentration of insulin, glucose, free fatty acids (FFA), triglycerides, betahydroxybutyrate, and acetoacetate in comparison to those changes occuring in five nondiabetic control subjects tested under identical experimental conditions. Our results demonstrate that in the absence of endogenous insulin secretion, exogenous glucagon administration results in an enhanced ketonemia indipendent of the rise of FFA substrate. This augmented ketogenic response to glucagon in diabetic subjects was not reflected in the dynamics of glucose regulation, with similar changes in blood glucose concentration occurring in both diabetic and nondiabetic populations. These data demonstrate that glucagon may potentiate ketonemia in insulin-deficient diabetics, although the mechanism mediating this augmentation is not defined. Since the rise in FFA substrate was indistinguishable in the diabetic as compared to the control group, increased hepatic conversion of FFA substrate into ketone bodies is suggested.
Regulation of Ketone Body Metabolism and the Role of PPARα.
Grabacka M, Pierzchalska M, Dean M, Reiss K Int J Mol Sci. 2016; 17(12).
PMID: 27983603 PMC: 5187893. DOI: 10.3390/ijms17122093.
Bonora E, Orioli S, Coscelli C, Buzzelli G, Gentilini P, BUTTURINI U Acta Diabetol Lat. 1984; 21(3):241-50.
PMID: 6393673 DOI: 10.1007/BF02642897.
Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy.
Del Prato S, Tiengo A, Baccaglini U, Tremolada C, Duner E, Marescotti M Diabetologia. 1983; 25(3):252-9.
PMID: 6357912 DOI: 10.1007/BF00279939.
Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.
Diem P, Robertson R Br J Clin Pharmacol. 1991; 32(5):563-7.
PMID: 1954071 PMC: 1368631. DOI: 10.1111/j.1365-2125.1991.tb03952.x.
Luyckx A, Lefebvre P Diabetologia. 1976; 12(5):447-53.
PMID: 976635 DOI: 10.1007/BF01219508.